SCHEMBL273681

SCHEMBL273681

O=C(Nc1ccc(Br)cc1C(=O)N/N=C/c1ccc(F)cc1)c1cccc(CSc2ccncc2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 5/20 0.51
LMNA P02545 4/20 0.51
SLC34A2 O95436 1/20 0.49
SLC34A1 Q06495 1/20 0.49
SLC34A3 Q8N130 1/20 0.49
SLC20A1 Q8WUM9 1/20 0.49
RAB9A P51151 6/20 0.47
NPC1 O15118 6/20 0.47
PKM P14618 2/20 0.47
MAPT P10636 5/20 0.46
ALDH1A1 P00352 4/20 0.46
KMT2A Q03164 7/20 0.46
MEN1 O00255 5/20 0.46
HTT P42858 1/20 0.45
SMN1; SMN2 Q16637 4/20 0.44
TDP1 Q9NUW8 2/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
GAA P10253 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL266977 1.00 POLB (0.51) POLBLMNASLC34A2SLC34A1SLC34A3
SCHEMBL274060 0.93 SLC34A2 (0.57) POLBLMNASLC34A2SLC34A1SLC34A3
SCHEMBL265319 0.93 SLC34A2 (0.57) POLBLMNASLC34A2SLC34A1SLC34A3
SCHEMBL273530 0.92 LMNA (0.51) POLBLMNASLC34A2SLC34A1SLC34A3
SCHEMBL266695 0.92 LMNA (0.51) POLBLMNASLC34A2SLC34A1SLC34A3
SCHEMBL273396 0.91 NPC1 (0.51) POLBLMNARAB9ANPC1PKM
SCHEMBL269020 0.91 NPC1 (0.51) POLBLMNARAB9ANPC1PKM
SCHEMBL266993 0.89 POLB (0.48) POLBLMNASLC34A2SLC34A1SLC34A3
SCHEMBL273386 0.89 POLB (0.48) POLBLMNASLC34A2SLC34A1SLC34A3
SCHEMBL267155 0.88 LMNA (0.49) POLBLMNASLC34A2SLC34A1SLC34A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 POLB 3761/4885LMNA 1925/4885SLC34A2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.